EVFM Research and Charts

EVFM - Evofem Biosciences Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-07-30 (Delayed quote data 2025-05-01)

Last 0.01	Change ⇓ 0.00 (0.00%)	Volume 141,402
	Open 0.01	High 0.01	Low 0.01

8EMA (Daily) 0.01	40EMA (Daily) 0.01	50EMA (Daily) 0.01	STO (Daily) 0.000	MACD Hist (Daily) 0.000
8EMA (Weekly) 0.010	40EMA (Weekly) 0.02	50EMA (Weekly) 0.05	STO (Weekly) 0.000	MACD Hist (Weekly) 0.003


Company Profile
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The company is also evaluating its investigational drug candidate EVO100 vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.